Kiromic BioPharma completes expansion of manufacturing lab to support clinical trials


The 34,000-square-foot facility will allow Kiromic BioPharma to begin a cell therapy clinical trial for a product candidate by the end of the year.

Previous Why Bayer chose Cambridge to launch its cancer strategy
Next Schlafly inks joint venture with non-alcoholic craft brewer Wellbeing Brewing